Trial Disruptions In Uncertain Times: Q&A With 4G’s Barry Moore
By Deborah Borfitz
April 21, 2020| Study sponsors are facing an unprecedented level of clinical supply disruptions caused by the COVID-19 pandemic. For insights on the current struggles of clinical supply study managers, innovations being deployed and ways to build a more resilient supply chain for future trials, Clinical Research News spoke with Barry Moore at randomization and trial supply management provider 4G Clinical.
Moore is 4g’s newly appointed vice president of delivery, and the previous head of clinical supply solutions at GlaxoSmithKline (GSK). While at GSK, he also served as chairman of the Clinical Supply Blockchain Working Group, developer of a blockchain-powered iPhone app for pharmaceutical clinical supply chains.
Amy Ripston, 4G Clinical Vice President of Marketing, has over 20 years of B2B experience, of which she spent 9 years in the bio/pharmaceutical industry. Amy has a knack for identifying market trends, synthesizing content, engaging thought leaders, and connecting businesses with innovative solutions.